Compare First Citizens BancShares Inc (FCNCA) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Citizens BancShares Inc vs TransMedics Group Inc — how do they compare? First Citizens BancShares Inc trades at $2,277.66 (market cap $25.04B), while TransMedics Group Inc trades at $87.31 (market cap $3.10B). The key difference: First Citizens BancShares Inc is far larger — about 8.1× TransMedics Group Inc's market cap, and First Citizens BancShares Inc pays a 0.37% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| FCNCA | TMDX | |
|---|---|---|
Market Cap | $25.04B | $3.10B |
Sector | Sector/Thematic | Technology |
52-Week High | $2.25K | $150.42 |
52-Week Low | $1.64K | $61.99 |
Dividend Yield | 0.37% | — |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Citizens BancShares (FCNCA) trades at $2,276, up 1.91% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 12.08 and net income margin of 25.23%, supported by recent earnings beats. Recent news highlights business expansion, including new financing groups and real estate acquisitions.
Outlook is positive with analyst consensus price target of $2,310, though most analysts rate it Hold. Key risks include elevated uninsured deposits and net interest margin pressure. Earnings growth and strategic initiatives provide upside potential, but investor caution is warranted near current levels.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
